Key Documents

View All Documentation

SML3710

Linaclotide

Name: Linaclotide
Brand: SIGMA

≥95% (HPLC), GC-C agonist, (Powder or Lyophilized powder or film)

Synonym(s):

CCEFCCNPACTGCF-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide), Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide), L-Cysteinyl-L-cysteinyl-L-α-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-tyrosine-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide)

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₅₉H₇₉N₁₅O₂₁S₆

CAS Number:

851199-59-2

Molecular Weight:

1526.74

UNSPSC Code:

12352200

NACRES:

NA.77

Assay:

≥95% (HPLC)

Form:

(Powder or Lyophilized powder or film)

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Linaclotide, ≥95% (HPLC)

Quality Level

100

assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

storage condition

desiccated

color

white to off-white

storage temp.

-10 to -25°C

SMILES string

S1SC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CSSC4)N)C1)CCC(=O)O)Cc6ccc(cc6)O)CSSC[C@H](NC(=O)CNC(=O)C(NC2=O)[C@H](O)C)C(=O)N[C@@H](Cc5ccc(cc5)O)C(=O)O)CC(=O)N)C

InChI

1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-

InChI key

KXGCNMMJRFDFNR-IURAOCFRSA-N

Related Categories

Bioactive Small Molecules

Biochem/physiol Actions

Linaclotide is an orally active guanylate cyclase-C (GC-C) agonist that competes against bacterial STa enterotoxin binding to intestinal mucosal membranes from wild-type, but not GC-C null, mice (Ki = 16.4 nM). Linaclotide stimulates fluid secretion, upregulates cGMP accumulation in the intestinal lumen (5 μg/100 μL via injection into surgically ligated intestinal loops), and significantly increases the rate of gastrointestinal transit when administered orally in mice in vivo (100 μg/kg p.o.).

Orally active guanylate cyclase-C (GC-C) agonist that elicits in vivo pharmacological effects locally in the gastrointestinal tract.

Disclaimer

Hygroscopic

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

常规特殊物品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000477032

0000457671

0000457190

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.

John Cuppoletti et al.

BMC pharmacology, 12, 3-3 (2012-05-05)

Linaclotide has been proposed as a treatment for the same gastrointestinal indications for which lubiprostone has been approved, chronic idiopathic constipation and irritable bowel syndrome with constipation. Stressors damage the epithelial cell barrier and cellular homeostasis leading to loss of

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Robert W Busby et al.

European journal of pharmacology, 649(1-3), 328-335 (2010-09-25)

Linaclotide is a first-in-class, orally administered 14-amino acid peptide that is in development for the treatment of irritable bowel syndrome with constipation and chronic constipation. We have characterized the solution structure of linaclotide, the in vitro binding and agonist activity

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

Alexander P Bryant et al.

Life sciences, 86(19-20), 760-765 (2010-03-24)

Linaclotide is an orally administered 14-amino acid peptide being developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. We determined the stability of linaclotide in the intestine, measured the oral bioavailability, and investigated whether the pharmacodynamic

Global Trade Item Number

SKU	GTIN
SML3710-25MG	04065269269069
SML3710-5MG	04065269269076

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service